BIOLASE Announces Preliminary Second Quarter Results

IRVINE, CA, Jul 07 (MARKET WIRE) --
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser
company, today announced that, based on a preliminary review of its
financial performance for the second quarter ended June 30, 2009, the
Company expects to report:

-- Net revenue estimates exceeding $13.5 million for the 2009 second
quarter, rebounding from $6.6 million in the previous quarter.

-- Gross margins as a percentage of revenue for the 2009 second quarter
returning to more historic ranges of between 45 percent and 55 percent, as
compared to 27 percent in the previous quarter.

-- Operating expenses continuing to reflect the impact of cost reduction
programs recently completed.

-- Net income and cash flows to be positive for the 2009 second quarter.

BIOLASE Chief Executive Officer David M. Mulder said, "During
difficult economic times -- when our doctors need it most -- we have
worked very hard alongside our primary partner Henry Schein, Inc.
(NASDAQ: HSIC) to spread the benefits of Waterlase*Dentistry across the
world. Our new distribution commitments, aggressive new sales and
marketing programs, and our new Waterlase MD Turbo(TM) launch were all
key factors in recent improvements. We continue to look strategically to
the future and continue to invest in research and development on our
annual $4 million R&D plan, but given the current economic environment we
remain cautious in our expectations and vigilant on cost-control
measures."

The Company will provide additional details on a quarterly conference call
and webcast when it reports full financial results in August.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading
dental laser company, develops, manufactures and markets Waterlase
technology and lasers and related products that advance the practice of
dentistry and medicine. The Company's products incorporate patented and
patent pending technologies designed to provide clinically superior
performance with reduced pain, faster and biological recovery times.
BIOLASE's principal products are dental laser systems that perform a broad
range of dental procedures, including cosmetic and complex surgical
applications. Other products under development address ophthalmology, pain
management and other medical and consumer markets.

This press release may contain forward-looking statements within the
meaning of safe harbor provided by the Securities Reform Act of 1995 that
are based on the current expectations and estimates by our management.
These forward-looking statements can be identified through the use of
words such as "anticipates," "expects," "intends," "plans," "believes,"
"seeks," "estimates," "may," "will," and variations of these words or
similar expressions. Forward-looking statements are based on management's
current, preliminary expectations and are subject to risks, uncertainties
and other factors which may cause the Company's actual results to differ
materially from the statements contained herein, and are described in the
Company's reports it files with the Securities and Exchange Commission,
including its annual and quarterly reports. No undue reliance should be
placed on forward-looking statements. Such information is subject to
change, and we undertake no obligation to update such statements.

For further information, please contact:
Jill Bertotti
Allen & Caron
+1-949-474-4300

Copyright 2009, Market Wire, All rights reserved.

-0-